BioCryst Pharmaceuticals is tackling the bad enzymes that spread disease. The firm creates small molecule compounds that inhibit enzymes associated with viral diseases, autoimmune conditions, and cancer. BioCryst's most advanced candidate is influenza inhibitor peramavir. It is being developed with funding from the Department of Health and Human Services. Its other main candidate is fodosine, an enzyme inhibitor that suppresses T-cells. It is being investigated as a treatment for T-cell cancers, including some lymphomas and leukemias, by preventing T-cells from wildly multiplying and harming the body. Another candidates in clinical development is an enzyme inhibitor for the treatment of gout.